/

KYNB

Kyntra Bio, Inc.Closed

5.87−0.25 −4.08%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delay

Open

6.21

Prev close

6.12

Day range

5.876.21

52-week range

5.6211.65

Volume

15.93K0.88×

Mkt cap

23.77M

P/E ttm

—

Fwd P/E

-0.41

EPS ttm

-7.64

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−49.61%

Price Chart

Yahoo Finance · delayed

KYNBOct 12, 2026O 6.15H 6.34L 6.01C 6.12+0.01 (+0.16%)Vol 23.60K

SMA 507.25
SMA 2007.39

1Y change −41.99% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KYNB Kyntra Bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.49%
1 month: −23.21%
3 months: −16.68%
6 months: −13.56%
Year to date: −30.30%
1 year: −41.99%

Valuation & ownership

Market cap: 23.77M
Enterprise value: −45.55M
P/E (ttm): —
Forward P/E: -0.41
PEG ratio: —
Price / book: —
Price / sales (ttm): 5.15
EV / EBITDA: 0.91
EPS (ttm): -7.64
EPS (forward): -14.23
Beta (5y monthly): 1.05
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 4.05M
Float: 3.57M
Short % of float: 2.52%
Short ratio (days): 3.87
Held by insiders: 2.02%
Held by institutions: 24.68%
Avg volume (3m): 18.18K
50-day average: 7.25
200-day average: 7.39
52-week change: −41.99%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 31.2
vs 50-day SMA: −15.57%
vs 200-day SMA: −17.14%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 6.14%
Realised vol (20d, ann.): 37.2%
From 52-week high: −47.47%
From 52-week low: +8.90%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

39.67

+575.75% implied

Low 35.00Median 41.00High 43.00

Recommendation trend

Now3 / 1 / 0
1m ago2 / 1 / 0

DES

About Kyntra Bio, Inc.

Yahoo Finance profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 34
Headquarters: San Francisco, CA, United States
Website: kyntrabio.com
Officers: Mr. Thane Wettig CEO & Director
Mr. David DeLucia Senior VP & CFO
Mr. John Alden Corporate Secretary & General Counsel
Ms. Michelle Simonetti

SEAS

Seasonality · KYNB

2014–2026 · monthly returns

Strongest month Jan +19.67%Weakest month Apr −13.38%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-10.3	-12.1	-2.2	7.2	-5.1	9.4	-10.9	15.6	-14.5	-11.7			−33.1%
2025	-8.7	-15.7	-24.0	9.0	-14.8	-26.4	30.6	71.0	3.6	-9.2	-20.9	-0.2	−33.7%
2024	116.7	-10.9	37.4	-52.3	7.1	-25.7	-39.5	-32.2	9.0	-24.6	41.2	24.7	−40.2%
2023	47.3	-5.9	-15.9	-8.3	0.8	-84.3	-23.7	-53.4	-10.1	-37.3	2.0	60.5	−94.5%
2022	7.0	-6.8	-14.6	-22.6	5.8	7.3	19.1	-1.1	4.6	25.1	-11.7	11.5	+13.6%
2021	29.9	3.8	-30.6	-35.7	-4.8	25.3	-51.2	-10.5	-12.1	8.8	12.5	12.7	−62.0%
2020	-2.4	-0.1	-16.9	6.2	-9.4	21.2	-0.1	10.8	-8.3	-6.7	7.6	-10.2	−13.5%
2019	22.6	1.9	-6.0	-14.0	-22.4	24.7	4.6	-5.5	-17.2	5.9	8.2	1.2	−7.3%
2018	23.5	-5.9	-16.2	-1.6	18.6	16.1	0.8	-3.1	-0.7	-29.4	1.1	6.7	−2.4%
2017	5.8	10.4	-1.4	13.6	-6.1	22.8	5.7	41.1	11.6	3.8	-15.0	-0.2	+121.5%
2016	-33.4	-14.5	22.9	-15.5	3.7	-12.1	16.6	-9.5	19.6	-20.0	33.8	-3.4	−29.8%
2015	8.0	7.8	-1.4	-25.9	-21.7	29.0	-1.1	5.4	-10.5	6.3	27.6	2.5	+11.4%
2014												20.7	+20.7%

INSD

Insider Activity · KYNB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 13, 2026	Wettig ThaneChief Executive Officer	Purchase at price 7.09 per share.	2.8K	$19.85K
May 13, 2026	Wettig ThaneChief Executive Officer	Purchase at price 7.09 per share.	2.8K	$19.85K
Nov 16, 2025	Wettig ThaneChief Executive Officer	Purchase at price 9.10 - 9.18 per share.	3.7K	$33.75K
Jun 29, 2025	Schoeneck James ADirector	Purchase at price 5.07 per share.	23.6K	$119.48K
Mar 23, 2025	Wettig ThaneChief Executive Officer	Purchase at price 0.35 per share.	145K	$50.66K
Mar 20, 2025	Schoeneck James ADirector	Purchase at price 0.34 - 0.35 per share.	300K	$105.04K
Mar 5, 2025	Wettig ThaneChief Executive Officer	—	781	—
Mar 5, 2025	Chung ChristineOfficer	—	781	—

13F

Investors Holding KYNB

latest 13F filings of 29 followed managers

Investors holding KYNB
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$204.5K	0.00%	27.08K	−1.5%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

KYNB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KYNB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kyntra Bio, Inc.

Seasonality · KYNB

Insider Activity · KYNB

Congress Trades · KYNB

Investors Holding KYNB

Investors Holding KYNB

Congress Trades · KYNB

Insider Activity · KYNB

Seasonality · KYNB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Kyntra Bio, Inc.

Financial Snapshot

Earnings & Dividends

News